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Hypothalamic neuropeptide Y (NPY) is implicated in the regulation of a variety of 
physiological functions, notably energy homeostasis and reproduction. Chronically elevated 
NPY levels in the hypothalamus, as in genetically obese ob/ob mice, are associated with 
obesity, a syndrome of type 2 diabetes, and infertility. However, it is not known which of the 
five cloned Y receptors mediate these effects. Here, we show that crossing the Y2 receptor 
knockout mouse (Y2<sup>-/-</sup>) onto the ob/ob background attenuates the increased 
adiposity, hyperinsulinemia, hyperglycemia, and increased hypothalamo-pituitary-adrenal 
(HPA) axis activity of ob/ob mice. Compared with lean controls, ob/ob mice had elevated 
expression of NPY and agouti-related protein (AgRP) mRNA in the arcuate nucleus and 
decreased expression of proopiomelanocortin (POMC) and cocaine- and amphetamine-
regulated transcript (CART) mRNA. Y2 deletion in ob/ob mice significantly increased the 
hypothalamic POMC mRNA expression, with no effect on NPY, AgRP, or CART expression. 
[Y2<sup>-/-</sup>ob/ob] mice were no different from ob/ob littermates with respect to food 
intake and body weight, and Y2 receptor deficiency had no beneficial effect on the infertility or 
the reduced hypothalamo-pituitary-gonadotropic function of ob/ob mice. These data 
demonstrate that Y2 receptors mediate the obese type 2 diabetes phenotype of ob/ob mice, 
possibly via alterations in melanocortin tonus in the arcuate nucleus and/or effects on the 
HPA axis. 
 
Abbreviations:  AgRP, agouti-related protein; BAT, brown adipose tissue; CART, cocaine- and 
amphetamine-regulated transcript; CRH, corticotropin-releasing hormone; DEXA, dual-energy X-ray 
absorptiometry; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPA, hypothalamo-pituitary-
adrenal; NPY, neuropeptide Y; POMC, proopiomelanocortin; PVN, paraventricular nucleus; TRH, 
thyrotropin-releasing hormone; UCP-1, uncoupling protein-1; WAT, white adipose tissue. 
 
 
Neuropeptide Y (NPY) in the hypothalamus is known to be a strong stimulus for food intake 
(1, 2) and induces many neuroendocrine and metabolic changes that favor energy storage. 
Such changes include decreased thermogenesis in brown adipose tissue (BAT) (3), 
hyperinsulinemia, insulin resistance in muscles, insulin hyperresponsiveness in white adipose 
tissue (WAT) (4), activation of the hypothalamo-pituitary-adrenal (HPA) axis (4,5), and 
decreased activity of the hypothalamo-pituitary-thyrotropic (6), -somatotropic, and -
gonadotropic axes (7). All of these adipogenic neuroendocrine and metabolic effects of 
central NPY administration persist, even when NPY-induced hyperphagia is prevented by 
pair-feeding (3,4,6,8), demonstrating that hyperphagia is not the only mechanism by which 
central NPY increases adiposity. However, it is not clear which of the five cloned Y receptors 
(Y1, Y2, Y4, Y5, and y6) are responsible for these effects. 
 
  The Y2 receptor is expressed in the central and peripheral nervous system. High 
concentrations of Y2 receptors can be found on NPY-ergic neurons in the hypothalamic 
arcuate nucleus (9,10), where it is thought to act as an inhibitory autoreceptor that can 
regulate the expression and secretion of NPY and other neurotransmitters (11-13). These 
arcuate neurons are also known to express the leptin receptor (14) and are located in an area 
accessible to peripheral hormones (15), enabling modulation of hypothalamic circuits 
important in the maintenance of energy homeostasis. 
 
Sainsbury	  et	  al.:	  Y2	  receptor	  deletion	  attenuates	  the	  type	  2	  diabetic	  syndrome	  of	  ob/ob	  mice	  
Diabetes,	  51(12):	  3420-­‐3427,	  2002	  	  	  
  Previously, we have shown that germline as well as conditional hypothalamus-specific Y2 
receptor deletion in mice resulted in reduced body weight despite an actual increase in food 
intake (16). Since the NPY-ergic system regulates energy homeostasis by interaction with a 
variety of pathways and hormones, including glucocorticoids (17-19) and leptin (20), we 
hypothesized that Y2 receptor deletion may alter energy homeostasis by interfering with such 
interactions. To investigate this possibility and to see whether the Y2 receptor plays a role in 
mediating the obese type 2 diabetes phenotype that results from leptin deficiency, we studied 
hormonal and metabolic indices and expression patterns of important central regulators of 
energy homeostasis in mice deficient in Y2 receptors as well as leptin. 
 
RESEARCH DESIGN AND METHODS 
Generation of [Y2-/-ob/ob] double knockout mice. Male and female heterozygous (OB/ob) 
mice on a mixed C57BL/6-129/SvJ background were crossed with Y2-/- animals (16) that 
were on the same mixed background. Double heterozygous [Y2+/-OB/ob] animals were 
crossed again to subsequently obtain all of the nine possible genotypes. The ob genotype 
was determined by restriction fragment-length polymorphism analysis using the enzyme DdeI 
on a 496-bp PCR product generated from genomic DNA isolated from these mice with the 
primer set A (5′-GAGTCAAGCATTGTGGAGT-3′) and B (5′-CAGTCGGTATCCGCCAAG-3′), 
with 35 cycles of 94 Celsius for 45 s, 55 Celsius for 1 min, and 72 Celsius for 20 s (21). 
Tissue collection and analysis. At 16-18 weeks of age, male mice were killed by cervical 
dislocation in the morning, 4 h after removal of food from cages, for collection of trunk blood. 
Mice were killed within 90 s of initial handling to avoid time-dependent increases in 
corticosteronemia (22). Interscapular BAT was removed and frozen until analysis for 
uncoupling protein-1 (UCP-1) mRNA levels, standardized with respect to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) mRNA, and expressed as a percent of control values, 
as previously described (23). Brain was removed and immediately frozen on dry ice, and 
WAT depots (right inguinal, right epididymal, right retroperitoneal, and mesenteric), pancreas, 
entire small intestine (flushed), liver, right kidney, and right testes were collected and 
weighed. The length of the small intestine was measured before flushing. Plasma insulin 
levels were measured by radioimmunoassay kits from Linco Research (St. Louis, MO), 
plasma levels of corticosterone, free T4, and testosterone were measured with 
radioimmunoassay kits from ICN Biomedicals (Costa Mesa, CA); plasma IGF-1 
concentrations were radioimmunoassayed with a kit from Bioclone Australia (Marrickville, 
Australia); and glycemia, cholesterolemia, and triglyceridemia were determined with 
colorimetric kits (Trace Scientific, Melbourne, Australia; Roche Diagonostics, Mannheim, 
Germany; and Sigma Diagnostics, St. Louis, MO). A subset of mice were used for 
determination of lean body mass by dual-energy X-ray absorptiometry (DEXA) (pDEXA Sabre 
with small animal software; Norland Medical Systems, Fort Atkinson, WI). 
In situ hybridization. Coronal slices (20 µm) of frozen brain were cut and thaw-mounted on 
charged slides. For in situ hybridization, DNA oligonucleotides complementary to mouse NPY 
(5′-GAGGGTCAGTCCACACAGCCCCATTCGCTTGTTACCTAGCAT-3′),proopiomelanocortin 
(POMC) (5′-TGGCTGCTCTCCAGGCACCAGCTCC ACACATCTATGGAGG-3′), cocaine- 
and amphetamine-regulated transcript (CART) (5′-TCCTTCTCGTGGGACGCATCATCCAC 
GGCAGAGTAGATGTCCAGG-3′), agouti-related protein (AgRP) (5′-AGCTTGCGGCA 
GTAGCAAAAGGCATTGAAGAAGCGGCAGT-AGCAC-3′), corticotropin-releasing hormone 
(CRH) (5′-CCGATAATCTCCATCAGTTTCCTGTTGCTGTGA GCTTGCTGAGCT), and 
thyrotropin-releasing hormone (TRH) 5′-AACCTTACTCCT CCAGAGGTT CCCTGACCCAGG 
CTTCCAGTTGTG-3′) mRNAs were labeled with [35S] thio-dATP (Amersham, 
Buckinghamshire, U.K.) using terminal deoxynucleotidyltransferase (Roche, Mannheim, 
Germany). Matching sections from the same portion of the hypothalamus (approximately -1.8 
mm [for POMC and CART] to -1.9 mm [NPY and AgRP] from Bregma for arcuate neurons 
and about -0.8 mm from Bregma for the paraventricular nucleus [PVN]) of knockout and wild-
type mice were assayed together, as described previously (16). Hybridization with the 
respective sense oligonucleotides and in the presence of an excess of unlabeled antisense 
oligonucleotide were included as controls. 
  For evaluation of in situ hybridization, digital images of the areas of interest were acquired 
from photoemulsion-dipped and superficially counterstained brain slices at 200x magnification 
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using a Zeiss Axiophot equipped with the ProgRes digital camera. Silver grain density was 
evaluated by an experimentally blinded observer by outlining single neurons and measuring 
the total neuronal area and the area covered by silver grains (black grains in brightfield 
image) using National Institutes of Health image software. Percent of silver grain area, 
compared with total area calculated for single neurons, was averaged. Data are given as 
percent of control silver grain density averaged from at least four sections per peptide per 
animal. 
  Radioligand-binding studies were carried out on sections consecutive to those used for in 
situ hybridization (approximately -2.1 from Bregma), as previously described (24), using the 
Y2/Y5-prefering ligand 125I-PYY(3-36). Autoradiographs were scanned, and relative optical 
density values were determined over the strata radiatum and oriens of hippocampal area CA3 
(delineated by the lateral ventricle and fimbria [the line connecting the ends of the two blades 
of molecular layer], the border to the stratum lacunosum moleculare, and approximately the 
border to CA2) and over the arcuate nucleus (using a higher magnification) and the lateral 
hypothalamus (measured lateral to the axes fornix-mammillothalamic tract). Specific binding 
was calculated by subtracting nonspecific (obtained from sections incubated in 1,000-fold 
excess of cold NPY) from total binding. Nonspecific labeling was uniform and never exceeded 
5% of total signal in control CA3. 
Statistical analyses. Before analysis, F tests were performed on all datasets to ensure 
nonsignificant differences in variance among the three groups of mice, justifying the use of 
parametric analyses. Results were assessed by factorial ANOVA. When there was a 
significant overall effect of Y2 deficiency, the ob locus, or interaction effects (P values shown 
in RESULTS), Fisher's posthoc tests were performed to locate differences, using StatView 
version 4.5 (Abacus Concepts, Piscataway, NJ). For all statistical analyses, P < 0.05 was 
accepted as statistically significant. 
 
RESULTS 
Reduced adiposity and normalization of insulinemia, glycemia, and thermogenic 
properties in [Y2-/-ob/ob] mice. The impact of Y2 receptor deficiency on body weight and 
adiposity of leptin-deficient ob/ob male mice is shown in Fig. 1. The higher body weight of 
ob/ob mice, as compared with wild-type mice, was unaffected by Y2 receptor deficiency (Fig. 
1A). Hyperphagia of [Y2-/-ob/ob] double knockout mice at 12 weeks of age was also not 
different from ob/ob mice, and food intake was 6.96 ± 0.47 vs. 6.12 ± 0.12 g/day in ob/ob 
mice (means ± SE of six mice per group). However, the increased combined WAT mass of 
ob/ob compared with wild-type mice (Fig. 1B) was significantly reduced in [Y2-/-ob/ob] double 
knockout mice. This effect of Y2 deletion was also observed when WAT was expressed as 
percent of body weight (wild-type 2.32 ± 0.13, n = 12; ob/ob 8.01 ± 0.31, n = 15; [Y2-/-ob/ob] 
6.88 ± 0.20, n = 8; overall P < 0.0001, posthoc P < 0.01 for all comparisons). It is interesting 
to note that these decreases in the sum of WAT mass in [Y2-/-ob/ob] mice were mostly 
attributable to significant decreases in epididymal and mesenteric depot weights, with no 
significant decrease in inguinal or retroperitoneal WAT depot weights (Fig. 1B). 
  Whereas ob/ob mice demonstrated significant hyperinsulinemia compared with wild-type 
controls, the insulinemia of [Y2-/-ob/ob] mice was 50% less than corresponding values in 
ob/ob mice and was not significantly different from wild-type values (Fig. 2A). Moreover, the 
marked hyperglycemia of ob/ob mice was significantly reduced by ablation of Y2 receptors, 
with [Y2-/-ob/ob] mice attaining values similar to wild-type mice (Fig. 2B). 
The expression of UCP-1 mRNA in BAT, which is an index of thermogenic activity in a variety 
of situations (25), is substantially reduced in ob/ob mice relative to wild-type mice (Fig. 1C). 
Deletion of the Y2 receptor on the ob/ob background restored the UCP-1 mRNA levels to 
wild-type values (Fig. 2C), suggesting an increased thermogenic activity that may have 
contributed to the reduced fat mass in the double knockout animals. 
  Interestingly, the intestinal hypertrophy observed in ob/ob mice was significantly attenuated 
in [Y2-/-ob/ob] double knockout mice, with no significant effect on intestinal length (Table 1). 
Kidney size was also significantly reduced by Y2 receptor deletion in [Y2-/-ob/ob] mice (Table 
1). However, cholesterolemia, triglyceridemia, and liver and pancreas weight, which are all 
markedly increased in ob/ob as compared with wild-type mice, were not affected by deletion 
of the Y2 receptor in [Y2-/-ob/ob] mice (Table 1). 
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Inhibitory effect of germline Y2 receptor knockout on the HPA axis of ob/ob mice. The 
effect of leptin and/or Y2 receptor deficiency on the HPA axis is depicted in Fig. 2D, Fig. 3, 
and Table 2. Y2 knockout per se significantly reduced the expression of CRH mRNA in the 
PVN compared with wild-type mice (Fig. 3 and Table 2), accompanied by a tendency to 
decrease in corticosteronemia (64 ± 17 ng/ml in Y2-/- on the lean background versus 102 ± 
32 ng/ml in wild-type mice, n = 10-18 male mice per group). Compared with wild-type, ob/ob 
mice had significant increases in both CRH mRNA expression levels in the PVN (Fig. 3 and  
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Table 2) and marked hypercorticosteronemia (Fig. 2D). Y2 receptor knockout in [Y2-/-ob/ob] 
mice not only reduced CRH mRNA levels in the PVN to values significantly less than wild-type 
controls (Fig. 3 and Table 2) but also normalized plasma concentrations of corticosterone 
compared with wild-type values (Fig. 2D). 
Effect of germline Y2 receptor knockout on the hypothalamo-pituitary-somatotropic 
axis of ob/ob mice. Since germline Y2 receptor deficiency significantly reduced fat mass in 
[Y2-/-ob/ob] mice compared with ob/ob controls in the absence of any reduction in body 
weight, we investigated whether changes in activity of the hypothalamo-pituitary-somatotropic 
axis may have occurred. Plasma levels of IGF-1, the main growth effector of the somatotropic 
axis, were significantly reduced in ob/ob mice compared with wild-type mice (Table 1), which  
Sainsbury	  et	  al.:	  Y2	  receptor	  deletion	  attenuates	  the	  type	  2	  diabetic	  syndrome	  of	  ob/ob	  mice	  
Diabetes,	  51(12):	  3420-­‐3427,	  2002	  	  	  
 
 
 
 
 
is in agreement with the known reduction in lean body mass in these mice( 26). By contrast, 
in [Y2-/-ob/ob] mice, the concentrations of IGF-1 were not significantly different from values of 
wild-type mice (Table 1). The whole-body lean mass (determined by DEXA) of [Y2-/-ob/ob] 
mice was greater than that of ob/ob controls, at 19.8 g (42.4% of body wt) vs. 16.0 g (32.7% 
of body wt), albeit lean body mass was less than that of wild-type mice, 25.2 g (87.3% of body 
wt), in both groups of obese animals. 
Effect of germline Y2 receptor knockout on the hypothalamo-pituitary-thyrotropic and -
gonadotropic axes of ob/ob mice. We also investigated the effect of Y2 receptor knockout 
on other hypothalamo-pituitary axes that are known to be dysregulated by hypothalamic NPY 
administration or leptin deficiency. Figure 3 and Table 2 show that the expression of TRH 
mRNA in the PVN was significantly increased in ob/ob mice versus wild-type controls and that 
these values were significantly reduced in both Y2-/- and [Y2-/-ob/ob] mice. Elevated TRH 
mRNA expression was also observed in ob/ob mice in the lateral hypothalamus, but in 
contrast to the PVN, no influence of Y2 deficiency was evident in the lateral hypothalamus 
(Table 2). These changes in central TRH expression were not reflected by changes in plasma 
concentrations of free T4 (Table 1), which showed no significant difference among the groups 
of mice investigated. Leptin-deficient ob/ob mice exhibit profound inhibition of the 
hypothalamo-pituitary-gonadotropic axis, exemplified in this study by the significant reductions 
in plasma testosterone levels, testicular weight (Table 1), and sterility (only one of eight male 
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ob/ob mice paired with fertile OB/ob females were able to produce live offspring). Y2 receptor 
knockout had no impact on these parameters of reproductive function in [Y2-/-ob/ob] mice 
(Table 1), and male [Y2-/-ob/ob] animals paired with fertile [Y2-/-OB/ob] females were unable 
to produce offspring (n = 5 breeding pairs). 
Altered expression levels of neuropeptides in the arcuate nucleus of [Y2-/-ob/ob] 
double knockout mice. Because Y2 receptors are known to be expressed on NPY neurons 
in the arcuate nucleus, where they can modulate the expression and release of several 
important neurotransmitters, we determined the expression level of several hypothalamic 
peptides in the different models. All genetic modifications caused alterations in mRNA 
expression of the neuropeptides investigated in the arcuate nucleus (Fig. 3 and Table 2). Y2 
deficiency increases NPY and AgRP mRNA levels, while POMC and CART mRNA levels are 
downregulated in the arcuate nucleus in Y2-/- compared with wild-type mice (Fig. 3 and Table 
2). As expected, leptin-deficient ob/ob mice exhibited marked increases in NPY and AgRP 
mRNA levels, accompanied by a strong suppression of POMC and CART mRNA expression 
(Fig. 3 and Table 2). [Y2-/-ob/ob] animals displayed mRNA levels for NPY, AgRP, and CART 
in the arcuate nucleus that were similar to those of ob/ob mice; however, POMC mRNA levels 
were doubled compared with ob/ob mice, suggesting a direct or indirect regulation of 
expression through Y2 receptors (Fig. 3 and Table 2). 
Altered binding levels for 125I-PYY(3-36) in [Y2-/-ob/ob] double knockout mice. To 
investigate whether Y2 receptor deletion mediates the observed alterations on hypothalamic 
functions via alteration in the expression of other Y receptors, we performed radioligand-
binding assays on brain slices. In wild-type and ob/ob mice, the binding of 125I-PYY(3-36), a 
Y2/Y5-preferring ligand, was highest in the strata radiatum and oriens of CA3 region in the 
hypocampus (Fig. 4 and Table 3). The binding levels in the hypothalamus of these groups 
were markedly lower than in the CA3 but were still well above the nonspecific binding, in line 
with previous studies (27). Binding levels were somewhat lower in the lateral hypothalamus of 
ob/ob than wild-type mice (Table 3). In contrast, both Y2-deficient mice groups displayed a 
pronounced drop in 125I-PYY(3-36) binding, rarely exceeding levels of nonspecific binding, 
confirming successful Y2 receptor deletion (Fig. 4 and Table 3). Interestingly, this finding also 
demonstrates a very low level of Y5 receptor expression in Y2-/- and [Y2-/-ob/ob] mice. 
 
 
 
DISCUSSION 
Here, we demonstrate that the obese type 2 diabetes phenotype of leptin-deficient ob/ob mice 
is partially mediated by signaling through Y2 receptors, since crossing our Y2 receptor 
knockout onto the ob/ob strain attenuated the increased adiposity, hyperinsulinemia, 
hyperglycemia, and increased HPA axis activity of these mice. 
  This study and our previous work have revealed an important regulation of the HPA axis by 
Y2 receptors. On a lean background as well as on the ob/ob background, Y2 receptor 
deficiency reduced CRH mRNA expression in the hypothalamic PVN and reduced plasma 
corticosterone concentrations. In addition to modulating output of the HPA axis, Y2 receptors 
also mediate responses to glucocorticoids. Whereas in wild-type mice corticosterone 
administration caused an obesity syndrome, Y2 knockout mice were not affected by this 
treatment, suggesting that excess glucocorticoids mediate their effects on energy balance, at 
least in part, through the Y2 receptor (16). 
  The improvement in hormonal and metabolic parameters in [Y2-/-ob/ob] versus ob/ob mice 
may be due to these reductions in HPA axis activity and responsiveness to endogenous 
glucocorticoids. Adrenalectomy is known to attenuate aspects of the obese type 2 diabetes 
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syndrome of leptin-deficient mice and rats, and the syndrome can be restored by specific 
administration of exogenous glucocorticoids (28-30), demonstrating a causal role of excess 
glucocorticoids in this syndrome. It is thought that adrenalectomy mediates improvements in 
hormonal and metabolic indices in obese rodents by normalizing activity of hypothalamic 
peptide systems that regulate hormonal-metabolic status and energy balance (31,32), notably 
by increased melanocortin tonus (33). Indeed, adrenalectomy normalized the elevated AgRP 
and reduced POMC mRNA levels in the hypothalamus of ob/ob mice to wild-type levels, with 
no significant effect on the increased NPY mRNA expression of these mice (33). Similarly, in 
[Y2-/-ob/ob] mice, the normalization of corticosteronemia may have contributed to the 
increased hypothalamic POMC expression compared with ob/ob animals, which may have 
improved hormonal and metabolic parameters by increasing melanocortin agonism by α 
melanocyte-stimulating hormone. 
  Besides an indirect effect via reduced HPA axis output, the increased hypothalamic POMC 
expression of [Y2-/-ob/ob] mice may be mediated by release of inhibitory effects of Y2 
receptors on POMC neurons within the hypothalamus. NPY-expressing neurons, which are 
known to coexpress the Y2 receptor (9) and contain GABA, make inhibitory synaptic contact 
with POMC neurons in the arcuate nucleus (34). It is possible that Y2 activation induces 
effects by inhibiting GABA-ergic transmission from NPY/GABA neurons, thereby releasing the 
inhibition of POMC neurons by GABA (34). 
  Y2 receptor deletion had no beneficial effect on the hyperphagia of ob/ob mice. Although 
increased hypothalamic NPY-ergic transmission mediates at least part of the hyperphagia of 
ob/ob mice (20), this effect is mediated via other receptors besides Y2, probably the Y1 
receptor. Hyperphagia was significantly reduced in ob/ob mice that had a null mutation in the 
Y1 receptor gene (35) but not in Y5 receptor-deficient ob/ob mice (36). Further evidence that 
Y1 receptors mediate hyperphagia in situations of elevated endogenous NPY-ergic tonus are 
the observations that fasting-induced refeeding is attenuated in Y1-/-( 37) but not in Y5-/-( 36) 
mice. In contrast, Y2 agonism actually decreases food intake. Acute or chronic administration 
of the Y2-preferring agonist NPY (13-36) to normal rats decreased overnight feeding (38) and 
daily food intake (7). More importantly, it has been shown that the gut-derived peptide PYY 
(3-36), released postprandially, reduces food intake in humans and rodents via activation of 
Y2 receptors (39). This hypophagic effect of Y2 receptor agonism may be mediated by 
decreased hypothalamic expression and secretion of NPY and AgRP (12,16). NPY release 
from hypothalamic slices is specifically inhibited by Y2 agonism (12). Furthermore, Y2 
deletion increases NPY and AgRP mRNA levels in the arcuate nucleus (16). The lack of effect 
of Y2 receptor knockout on hypothalamic NPY or AgRP expression, or on food intake in ob/ob 
mice, is likely due to already maximal levels of these parameters. 
  Although food intake was unaffected by Y2 receptor deficiency in [Y2-/-ob/ob] mice, it is 
likely that efficiency of nutrient absorption from the gut was reduced in [Y2-/-ob/ob] versus 
ob/ob mice, which probably contributed to the reduced fat mass of the double knockout mice. 
Evidence for this is our observation of reduced intestinal mass in [Y2-/-ob/ob] compared with 
ob/ob mice and the previous finding that increases in intestinal mass in ob/ob mice correlate 
with increased absorption of all nutrient groups (40). 
  Despite the significant reductions in fat mass, Y2 receptor deletion did not reduce the 
increased body weight of ob/ob mice. Changes in adipose tissue depot weights are not 
always associated with commensurate changes in body weight in experimental animals (23, 
37). This may be because changes in fat mass are often associated with opposite changes in 
lean mass. For instance, leptin-deficient and NPY-infused rodents have increased fat mass 
but decreased lean mass or naso-anal length and/or downregulation of the hypothalamo-
pituitary somatotropic axis (7,26,41). The reduced fat mass of [Y2-/-ob/ob] versus ob/ob mice 
was associated with increased plasma concentrations of IGF-1, suggesting improved function 
of the somatotropic axis, which may have contributed to an increase in lean mass in the 
former group. It is interesting to note that Y2 receptor deficiency on the lean background 
markedly increased bone density (42), in keeping with a role of Y2 receptors in the regulation 
of lean body mass. 
  This study shows that Y2 receptors are involved in a direct or indirect regulation of 
hypothalamic TRH expression, since TRH mRNA levels in the PVN were downregulated in 
Y2-/- and [Y2-/-ob/ob] mice compared with wild-type and ob/ob controls. This was not 
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associated with any effect on plasma concentrations of free T4. It is not clear how this change 
in central TRH expression affected functional activity of the hypothalamo-pituitary-thyroid axis, 
or whether any changes in thyrotropic function contributed to any of the observed metabolic 
changes in [Y2-/-ob/ob] mice, such as the increased expression of BAT UCP-1, which is 
regulated by thyroid hormones (43). 
  It is noteworthy that Y2 receptor deficiency attenuates aspects of the leptin-deficient 
phenotype that pertain to the metabolic syndrome, with no effect on the infertility and 
defective hypothalamo-pituitary-gonadotropic function of ob/ob mice. In contrast, Y4 receptor 
knockout specifically rescued the infertility of ob/ob mice, with no effect on fat mass, 
insulinemia, or glycemia. Null mutation of Y1 receptors in ob/ob mice attenuated not only the 
hyperphagia and increased body weight, but also the reduced gonadotropic function of these 
mice (35). These data clearly show that although increased hypothalamic NPY signaling 
contributes to the hyperphagia, obesity, hypercorticosteronemia, decreased somatotropic axis 
activity, and infertility of ob/ob mice (20), these different effects of leptin deficiency are 
mediated by distinct Y receptors. 
  In summary, Y2 receptor deletion attenuates the obese type 2 diabetes phenotype of ob/ob 
mice, without any effects on fertility. This may be mediated by increased central melanocortin 
agonism, indicated by increased POMC mRNA expression in the arcuate nucleus, which may 
be a direct effect of Y2 deletion, or secondary to reduced HPA axis activity in [Y2-/-ob/ob] 
mice. Y2-specific therapeutics may therefore be beneficial in the clinical management of 
obesity and type 2 diabetes, as well as in the treatment of osteoporosis, without side effects 
on reproductive function. 
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